GSK plc

GSK plc Equity

The The Equity of GSK plc (GSK.L) as of Nov 2, 2026 is 16.38 B GBP. In the previous year, The Equity was 13.67 B GBP — a change of 19.79% (higher).

Equity

16.38 BGBP

YoY

19.79%

Last updated:

In 2025, GSK plc's equity was 16.38 B GBP, a 19.79% increase from the 13.67 B GBP equity in the previous year.

The GSK plc Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.78 B GBP
Jan 1, 2019
11.41 B GBP
Jan 1, 2020
14.59 B GBP
Jan 1, 2021
15.06 B GBP
Jan 1, 2022
10.60 B GBP
Jan 1, 2023
13.35 B GBP
Jan 1, 2024
13.67 B GBP
Jan 1, 2025
16.38 B GBP
The GSK plc Equity history
YEAREquityYoY
16.38 BGBP+19.79%
13.67 BGBP+2.43%
13.35 BGBP+25.94%
10.60 BGBP-29.60%
15.06 BGBP+3.21%
14.59 BGBP+27.90%
11.41 BGBP+201.64%
3.78 BGBP-5,660.29%
-68.00 MGBP-106.05%
1.12 BGBP-78.02%
5.11 BGBP+19.96%
4.26 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Equity Details

Analyzing GSK plc's Equity

GSK plc's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding GSK plc's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating GSK plc's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

GSK plc's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in GSK plc’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about GSK plc stock

The Equity of GSK plc is 16.38 B GBP in 2025.

The Equity of GSK plc changed from 13.67 B GBP to 16.38 B GBP, representing a 19.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity GSK plc since 2006 – with annual values, charts, and detailed analysis.

The Equity's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc